CancerCareHomes

#Selpercatinib (Retevmo) - a highly selective RET kinase inhibitor used in cancers driven by RET gene alterations. 🔬 Mechanism: RET is a receptor tyrosine kinase that, when mutated or fused, becomes constitutively active → driving tumor growth. Selpercatinib inhibits RET signaling, blocking downstream pathways (MAPK, PI3K) and suppressing proliferation. Clinical use (biomarker-driven): • RET fusion–positive non-small cell #lung #cancer • RET-mutant medullary thyroid cancer • RET fusion–positive thyroid cancer (including radioactive iodine–refractory) • RET fusion–positive solid tumors

Conf Highlights #GU26 from #CommunityOnc: 1. #POSEIDON: recurrent CSPC 2. #PEACE3 mCRPC 3. #BRCAAway: HRRm mCRPC 4. #KEYNOTEB15: MIBC 5. #LITESPARK022: Adj RCC 6. #LITESPARK011: RCC 2L #OncTwitter #gusm @ASCO @OncoAlert @OncUpdates 1/7

Time teaches us that unhappiness is a phase everyone experiences—and that it passes. Life unfolds through opposing forces: happiness and sadness, abundance and scarcity. As we reflect on this truth, we are reminded of the essence of being human, and that no single moment defines a life. amazon.com/gp/aw/d/B0GD7F…

Whoever said “money can’t buy happiness” really knew what they were talking about 😔

More on resistance to ADCs @JTOonline. Studies of T-DXd (HER2 ADC) suggest a wide range of mechanisms including payload resistance (via SLFN11 loss and copy number gains of ABCC1/MRP1 efflux pump) and HER2 extracellular mutations, not just antigen loss. jto.org/article/S1556-…

OS update in #MARIPOSA trial (#Amivantamab plus #Osimertinib) #NSCLC #CancerResearch

🧬 🩸 Neoadjuvant chemo adds nothing to osimertinib in terms of ctDNA clearance or pathological responses in resectable EGFR mutant lung cancer (neoADAURA trial). In my mind, this somehow conflicts with the results from FLAURA -2 in the metastatic setting, where the addition of chemo to osimertinib improves clinical outcomes. Is because different biology (eg., less clonality in smaller tumors?) #WCLC25 #LCSM Thoughts?

Dr. @dplanchard at #WCLC25 with highly anticipated Presidential Plenary presentation with OS results from FLAURA2: first line chemo + osimertinib improves OS from 37.6 to 47.5m, HR 0.77, 4y OS rate 41% to 49%. Benefit seen across subgroups. Strong results - similar to MARIPOSA.

Nice slide for cross trial comparison Flaura , Flaura 2 amd Marriposa. by Dr Daniel Tan #WCLC2025 . Don't miss the last row .

VEGF/PD1 bispecifics presented #WCLC25 M1 NSCLC. Ivonescimab/chemo vs Placebo/Chem PFS HR 0.52 (0.41-0.66) & OS HR 0.79 (0.61-1.01). 11% ⬆️in RR. N=430 is small for a R3 and underpowered for significant OS. This class needs investing in combinations in renal and bladder cancer.

EGFR update 7 potential options: •3rd gen TKI: osimertinib, lazertinib, aumolertinib •Amivantamab •Pemetrexed •Carboplatin •Ivonescimab •Dato-DXd OS data favor combos upfront—but real-world ≠ trial. In RWD, ~40% of newly diagnosed pts wouldn’t qualify for FLAURA2 #WCLC25

OS benefit in CtDNA + population with adjuvant Atezolizumab

Just out: Current Treatment Algorithm — completely open access — for elderly patients with acute myeloid leukemia. AML. @BloodCancerJnl By @n_gangat @MayoClinic & Dr. Courtney Dinardo @MDAndersonNews Link: nature.com/articles/s4140…

⭐️#ASCO25 recap series part 2️⃣-🫁#LungCancer ⬇️ 1️⃣#IMforte 2️⃣#DeLLphi-304 3️⃣#CheckMate816 4️⃣#NeoADAURA 5️⃣Time of Day of Immunochemotherapy impact on survival in #NSCLC #Medtwitter #MedX #OncTwitter #CommunityOncology #Oncology #lcsm #MedEd @OncBrothers @ASCO @HemOncFellows

In the future we won’t rely on pathology at surgery +/- luck to select patients for adjuvant treatment across cancers. Instead, the identification of residual disease by ctDNA/other biomarkers will be used. These data are a step towards that goal IMO. natera.com/company/news/i…

DatoDXd is now approved for previously treated mEGFR NSCLC based off #TROPIONLung01 & 05! We had a chance to 🗣️ this trial, findings, AEs and sequencing w/ @sands_jacob Full 🗣️: ⭐️ oncbrothers.com/fda-datdxd-lun… ⭐️ Also on “Oncology Brothers” podcast #OncTwitter #lcsm

🚨 Trials to Watch – WCLC 2025 🚨 🔑 Plenary LBAs: FLAURA2: Osimertinib + Chemo (OS update) Aumolertinib + Chemo (EGFRm NSCLC) HARMONi-A: Ivonescimab + Chemo vs Chemo ARROS-1: Zidesamtinib (ROS1+) CheckMate 816: Neoadjuvant Nivolumab (OS) EA5181: Durvalumab + CRT in Stage III NADIM Adjuvant: Nivolumab + Chemo Oncology is moving fast—practice-changing data ahead! #WCLC25 @OncoAlert @OncBrothers @medicalwatchBC

Getting ready for #WCLC25 - the annual @IASLC World Conference on Lung Cancer will be in Barcelona, Spain September 6 to 9, 2025 - hear from this year's co-chairs about what to expect and how to prepare! @DrJNaidoo @UmbertoMalapel1 @NReguart @IsaOpitz iaslc.org/iaslc-news/lun…

FDA approves zongertinib 120mg po daily for previously treated advanced #HER2 NSCLC. In the phase 1b Beamion-LUNG 1 study @NEJM, RR 71% (42% post ADC), DOR 14.1m, intracranial RR 41%. Main toxicity is diarrhea (56%, 48% grade 1), no ILD. fda.gov/drugs/resource…

FDA Accelerated Approval Zongertinib (Hernexeos) for adults with HER2 (ERBB2) TKD-mutant unresectable/metastatic non-sq #NSCLC after prior therapy 🫁 ✅ ORR: 75% (no prior HER2-ADC) | 44% (post HER2-ADC) 💊 Daily oral TKI | Companion Dx: Oncomine Dx Target Test ⚠️ Watch for hepatotoxicity, LV dysfunction, ILD/pneumonitis A new targeted option — even post-T-DXd 💥 #LungCancer #Oncology #FDA #HER2 @OncoAlert @medicalwatchBC @OncBrothers

@OncBrothers @KuykendallMd @OncUpdates @BijoyTelivala @RenoHemonc @SuyogCancer @HemOncFellows @WilliamAird4 @sankalparoraMD @Dr_AmerZeidan @KMirza @MPN_RF @TalhaBadarMD In case of high risk PV with history of venous thrombosis - anticoagulation is preferred

Treatment Algorithm: This is the algorithm we have used during our discussion with @KuykendallMd on Polycythemia Vera and Essential Thrombocythemia! #OncTwitter #MedTwitter #HemeTwitter @OncUpdates